Biosergen AB Logo

Biosergen AB

Developing novel antifungal drugs for life-threatening infections in immunocompromised patients.

BIOSGN | ST

Overview

Corporate Details

ISIN(s):
SE0016013460 (+2 more)
LEI:
549300YD2OGUE7BMP925
Country:
Sweden
Address:
Fogdevreten 2, 171 65 Solna
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Biosergen AB is a clinical-stage biotechnology company dedicated to developing innovative treatments for life-threatening invasive fungal infections. The company's lead candidate, BSG005, is a genetically improved, fungicidal polyene macrolide designed to offer a superior safety and potency profile compared to current antifungal therapies. BSG005 targets a wide spectrum of fungal pathogens and is primarily being developed for immunocompromised patients, such as those undergoing cancer treatment or organ transplantation. Originating from research at the Norwegian University of Science and Technology, the drug has received FDA Orphan Drug Designation. Through clinical trials and strategic collaborations, Biosergen aims to address the significant unmet medical need in treating severe and resistant fungal diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Biosergen AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Biosergen AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Double Bond Pharmaceutical International AB Logo
Redeveloping drugs with proprietary delivery tech for oncology & infectious diseases.
Sweden DBP B
Develops & commercializes PET/CT tracers for diagnosing cancer & neurological disorders.
South Korea 176750
Dx & Vx Co., Ltd. Logo
Develops innovative diagnostics & vaccines and provides comprehensive life science contract services.
South Korea 180400
Manufactures vet pharma for livestock/aquaculture & distributes premium pet food.
South Korea 044960
ECO ANIMAL HEALTH GROUP PLC Logo
Develops pharmaceuticals for respiratory & enteric diseases in global swine and poultry markets.
United Kingdom EAH
Ectin Research AB Logo
Clinical-stage biotech developing novel cancer treatments, focusing on metastatic bladder cancer.
Sweden ECTIN B
Eevia Health Plc Logo
Manufactures validated polyphenol extracts from Arctic plants for the supplement & food industries.
Finland EEVIA
Egetis Therapeutics Logo
Develops and commercializes drugs for serious rare diseases with unmet medical needs.
Sweden EGTX
EIKEN CHEMICAL CO.,LTD. Logo
Manufacturer of clinical diagnostics, specializing in FIT systems for cancer and microbiological tests.
Japan 4549
Eisai Co., Ltd. Logo
A global, research-based pharmaceutical firm that develops and markets prescription and OTC drugs.
Japan 4523

Talk to a Data Expert

Have a question? We'll get back to you promptly.